An interventional study of Pulmonary rehabilitation (PR) in Pulmonary Embolism and Quality of Life and Dyspnea, sponsored by University Hospital, Brest. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pulmonary Embolism by University Hospital, Brest — 5 open to participants now, 6 under way, none of them phase 3. Pulmonary Embolism · University Hospital, Brest.
Among the 20 studies in Pulmonary Embolism by University Hospital, Brest, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 10 with no phase, and was the 15th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →5 of the 20 studies in Pulmonary Embolism by University Hospital, Brest are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
University Hospital, Brest · Sites in France
Ages 18–99
By country, each count listing its studies:
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 112 is below the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 374 across the 11 interventional studies, 374 across the 9 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Brest is the lead sponsor of 601 studies on the registry; 136 are open to participants now.
2 of the studies in Pulmonary Embolism by University Hospital, Brest that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103670University Hospital, BrestVentilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism | 2026-12-22 |
| NCT05015153University Hospital, BrestImpact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study | 2027-02-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Pulmonary Embolism by University Hospital, Brest, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pulmonary Embolism (PE) is a common and serious disease. Indeed, the annual incidence is 1/1000 patients per year and the 3-month mortality is 10%, which is twice that of myocardial infarction. The treatment is based on anticoagulation for at least 3 months. However, after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases. Several mechanisms explain dyspnea and impairment of quality of life after PE, such as residual pulmonary artery obstruction, exercise deconditioning, depressive syndrome or development of a cardio-respiratory pathology. Pulmonary rehabilitation (PR) has been shown to be effective on dyspnea and quality of life and is included in the therapeutic management of chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis. Furthermore, PR is also used after a myocardial infarction. However, PR after PE is still not included in therapeutic management of PE while outpatient management is recommended for the majority of patients after an acute PE episode. Study hypothesis is that PR has the potential to improve quality of life and dyspnea perception in patients who have received anticoagulation for at least 3 months after PE and who present an impairment of quality of life and/or a persistent dyspnea. This study presents several innovative aspects. First, to our knowledge, This study is the first large randomized trial assessing PR at least 3 months after acute symptomatic PE. Only one small randomized trial on 18 patients evaluating the impact of PR after PE has been published; as PR was performed just after the acute phase of PE in this trial, the clinical status improvement observed in this study could not be explained by PR alone, but also by anticoagulation. In this study, the investigators will include 112 patients at least 3 months after PE in order to exclude the bias related to anticoagulation effect. Second, This study is the first large randomized trial. Third, this study is the first that have the potential to demonstrate efficacy and safety of delayed PR after PE in patients with impaired quality of life due to persistent residual dyspnea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months
Other: Pulmonary rehabilitation (PR)
No Pulmonary rehabilitation
20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
Quality of life - PEmbQoL score
Pulmonary embolism Quality of life score. This score includes 6 items regarding the frequency of lung complaints, their intensity, their physical, personal, social and professional impact. For each item, an average score is collected
Time frame: 3 months
Safety : number and type of adverse reactions
Number of events
Time frame: 3 months
Quality of life - PEmbQoL score
Pulmonary embolism Quality of life score. This score includes 6 items regarding the frequency of lung complaints, their intensity, their physical, personal, social and professional impact. For each item, an average score is collected
Time frame: 15 months
Pulmonary Vascular Obstruction index
Pulmonary Vascular Obstruction (Meyer score) assessed with V/Q lung scan
Time frame: 3 months
Incidence of dyspnea
Multidimensional dyspnea Profile (MDP) at the cycloergometer, Borg scale at the cycloergometer and at the 6 minute-walk-test, and Modified Medical Research Council scale (MMRC)
Time frame: 3 months and 15 months
Change of 6 Minutes Walk Test
6 Minutes Walk Test
Time frame: 3 months and 15 months
Change of Psychological status
Score of Hospital Anxiety and Depression scale. 14 rated items from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), allowing thus obtaining two scores (maximum score for each score = 21)
Time frame: 3 months and 15 months
Symptomatic recurrent PE
Number of events
Time frame: 15 months
Arterial thromboembolic events
Number of events
Time frame: 15 months
Deaths of all causes
Number of events
Time frame: 15 months
Hospitalizations and acute medical events
Number of events
Time frame: 15 months
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available beginning five years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Feb 2027, 57 months after the start.
Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 57 months is above that.
Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.